BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 23152926)

  • 21. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes.
    Wibmer CK; Bhiman JN; Gray ES; Tumba N; Abdool Karim SS; Williamson C; Morris L; Moore PL
    PLoS Pathog; 2013 Oct; 9(10):e1003738. PubMed ID: 24204277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural Features of Broadly Neutralizing Antibodies and Rational Design of Vaccine.
    Zhou T; Xu K
    Adv Exp Med Biol; 2018; 1075():73-95. PubMed ID: 30030790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
    Zhang MY; Xiao X; Sidorov IA; Choudhry V; Cham F; Zhang PF; Bouma P; Zwick M; Choudhary A; Montefiori DC; Broder CC; Burton DR; Quinnan GV; Dimitrov DS
    J Virol; 2004 Sep; 78(17):9233-42. PubMed ID: 15308718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
    Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
    J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.
    Zhang Y; Chapman JH; Ulcay A; Sutton RE
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics of the earliest cross-neutralizing antibody response to HIV-1.
    Mikell I; Sather DN; Kalams SA; Altfeld M; Alter G; Stamatatos L
    PLoS Pathog; 2011 Jan; 7(1):e1001251. PubMed ID: 21249232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies.
    Deshpande S; Patil S; Kumar R; Shrivastava T; Srikrishnan AK; Murugavel KG; Koff WC; Chakrabarti BK; Bhattacharya J
    Retrovirology; 2016 Jun; 13(1):41. PubMed ID: 27307004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.
    Gift SK; Leaman DP; Zhang L; Kim AS; Zwick MB
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of Neutralizing Antibodies in HIV-1 Patients on Antiretroviral Treatment for Over Ten Years.
    Cao W; Wang X; Li B; Lin L; Du Z; Zhao H; Zhang Y; Xu Z; Qiao Y
    Clin Lab; 2019 Jul; 65(7):. PubMed ID: 31307159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
    Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site.
    Wibmer CK; Gorman J; Anthony CS; Mkhize NN; Druz A; York T; Schmidt SD; Labuschagne P; Louder MK; Bailer RT; Abdool Karim SS; Mascola JR; Williamson C; Moore PL; Kwong PD; Morris L
    J Virol; 2016 Nov; 90(22):10220-10235. PubMed ID: 27581986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses.
    Kumar S; Panda H; Makhdoomi MA; Mishra N; Safdari HA; Chawla H; Aggarwal H; Reddy ES; Lodha R; Kumar Kabra S; Chandele A; Dutta S; Luthra K
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30429339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.
    Feng Y; McKee K; Tran K; O'Dell S; Schmidt SD; Phogat A; Forsell MN; Karlsson Hedestam GB; Mascola JR; Wyatt RT
    J Biol Chem; 2012 Feb; 287(8):5673-86. PubMed ID: 22167180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins.
    Richard J; Pacheco B; Gohain N; Veillette M; Ding S; Alsahafi N; Tolbert WD; Prévost J; Chapleau JP; Coutu M; Jia M; Brassard N; Park J; Courter JR; Melillo B; Martin L; Tremblay C; Hahn BH; Kaufmann DE; Wu X; Smith AB; Sodroski J; Pazgier M; Finzi A
    EBioMedicine; 2016 Oct; 12():208-218. PubMed ID: 27633463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells.
    Rao PG; Lambert GS; Upadhyay C
    J Virol; 2023 Sep; 97(9):e0071023. PubMed ID: 37681958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.
    Leaman DP; Lee JH; Ward AB; Zwick MB
    J Virol; 2015 Jul; 89(13):6725-45. PubMed ID: 25878116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A facile method of mapping HIV-1 neutralizing epitopes using chemically masked cysteines and deep sequencing.
    Datta R; Roy Chowdhury R; Manjunath K; Hanna LE; Varadarajan R
    Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29584-29594. PubMed ID: 33168755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.
    Sather DN; Carbonetti S; Malherbe DC; Pissani F; Stuart AB; Hessell AJ; Gray MD; Mikell I; Kalams SA; Haigwood NL; Stamatatos L
    J Virol; 2014 Nov; 88(22):12968-81. PubMed ID: 25122781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.